Nascent Biotech EBITDA TCAC 3A

Que fait Nascent Biotech ? Nascent Biotech Inc is a clinical-stage biopharmaceutical company based in North Palm Beach, Florida. The company went public on June 6, 2012, with its ticker symbol NBIO and ISIN US63108Q1013. Nascent Biotech focuses on developing monoclonal antibodies for cancer treatment, particularly targeting epithelial cancers including lung, breast, colon, brain, and pancreatic cancers. The company's lead drug candidate, Pritumumab, is being developed for the treatment of various cancers, with an initial focus on brain cancer malignancies such as glioblastoma and malignant astrocytoma. Pritumumab is currently undergoing clinical testing, and the company is exploring its potential application against viruses. Additionally, Nascent Biotech is working on a traditional vaccine platform aimed at creating vaccines for viral infections. The company's website is https://www.nascentbiotech.com/. Nascent Biotech operates in the biopharmaceutical sector without specific industry classification, and its headquarters are located in North Palm Beach, United States. The company is engaged in the development of biologic drug candidates that are in or have completed initial clinical testing, with the goal of advancing these candidates toward commercial use. The company's activities are centered around innovative approaches to cancer therapy and viral infection prevention through biologic means. Nascent Biotech est l'une des entreprises les plus populaires sur Eulerpool.